Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Compounded Testosterone Troches to optimize Health and the Testosterone Controversy

Author(s):  Guth Michael AS

Issue:  May/Jun 2015 - Volume 19, Number 3
View All Articles in Issue

Abstract:  As men age, testosterone levels progressively fall and inflammatory biomarkers increase. The gradual decline in testosterone production with aging, known as andropause, is common and may have deleterious effects on men including decreased overall well-being, increased sarcopenia, increased risk of cardiovascular disease, reduced sexual function, and bone loss. Therefore, it comes as no surprise that an increasing number of men worldwide have begun requesting testosterone replacement therapy from their physicians. Occasionally, physicians discourage male patients from getting testosterone replacement therapy based on a few recent studies indicating the therapy causes cardiovascular events, including myocardial infarctions. Yet, an extensive review of the testosterone replacement therapy literature reveals that the majority of clinical studies show that properly administered testosterone replacement therapy, in which estradiol and dihydrotestosterone levels are also controlled, has no adverse effects on myocardial infarction risk. The current state-of the- art in testosterone replacement therapy comprises compounded testosterone troches; an aromatase inhibitor, such as generic Anastrazole, to control estradiol levels; and a 5a-reductase inhibitor, such as generic Dutasteride or Finasteride, to control dihydrotestosterone. Compounded testosterone troches easily raise serum testosterone levels to the optimal range, are highly cost effective at $82 for a 180-day supply, and provide affordable access to testosterone replacement therapy to millions of men requesting it. Yet, the Blue Cross Blue Shield-associated firms have largely denied requests for coverage of compounded medications, including testosterone troches. Despite data demonstrating strong links between testosterone deficiency and significant comorbid conditions (including Type 2 diabetes and other metabolic syndrome diseases) as well as the health benefits of testosterone replacement therapy, some physicians have been swayed against prescribing testosterone replacement therapy to their aging male patients. The testosterone controversy stems largely from poorly designed clinical studies in which patients were subjected to testosterone replacement therapy without having their estradiol and dihydrotestosterone levels properly controlled.

Related Keywords: Michael A.S. Guth, PhD, JD, men, aging, andropause, androgen deficiency, cholesterol transport, testosterone replacement therapy, estradiol, aromatase inhibitor, dihydrotestosterone, 5-alpha reductase inhibitor, cardiovascular events, risk factors, insurance coverage, formulation, drug cost, dosage forms, controversy, therapeutic monitoring, Blue Cross Blue Shield, reimbursement


Printer-Friendly Version

Download in electronic PDF format for $55

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Compounded Testosterone Troches to optimize Health and the Testosterone Controversy Guth Michael AS May/Jun 2015 195-203 Buy
Emerging Evidence for Androgen Replacement Therapy in Aging Men Bramwell Bethany L Mar/Apr 2010 94-99 Buy
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K Jan/Feb 2013 74-85 View Sample
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1 Cutter Christopher B Jan/Feb 2004 16-21 Buy
Andropause: New Perspectives Biundo Bruce May/Jun 2004 175-178 Buy
Testosterone Deficiency in Men: New Treatments for Andropause Biundo Bruce, Shippen Eugene Nov/Dec 2000 429-431 Buy
Impact of Conventional and Bioidentical Hormone Replacement Therapy on Cardiovascular and Breast Health: A Review Ruiz Andres D, Daniels Kelly R, Barner Jamie C, Carson John J, Frei Christopher R Jul/Aug 2011 290-300 Buy
The Science Behind Hormone Replacement Therapy, Part 1 Wepfer Scott T Nov/Dec 2001 462-464 Buy
Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy Glaser Rebecca L, York Anne E Jul/Aug 2019 325-339 Buy
Testosterone Levels in an Aging Population: Screen, Measure, and Restore Kells John, DollbaumCharles M Mar/Apr 2011 102-112 Buy